MANNKIND CORPORATION

MNKD · NASDAQ

Pharmaceutical Preparation Manufacturing · US

MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, its first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut.

Market Data

Price $3.92 +0.26 (+7.10%)

Market Cap$1.15B

P/E Ratio—

EPS$—

52W High$6.51

52W Low$2.23

Beta1.16

Data from Finnhub · Updated Jun 15, 2026